Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. Ezetimibe and atorvastatin are two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe/atorvastatin combination reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
|C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BA Combinations of various lipid modifying agents
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
|ATOZET Film-coated tablet
|Health Products Regulatory Authority (IE)
|MPI, EU: SmPC
Atorvastatin and Ezetimibe is an active ingredient of these brands:
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.